Ultragenyx Receives Positive Recommendation From NICE In The U.K. For Evkeeza For Adolescents And Adults Aged 12 Years And Older With Homozygous Familial Hypercholesterolemia
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) received a positive recommendation from NICE for Evkeeza (evinacumab) for patients 12 years and older with homozygous familial hypercholesterolemia (HoFH) in the U.K. Evkeeza is an ANGPTL3 inhibitor and is the first of its kind for this condition. Despite cost-effectiveness uncertainties, NICE found Evkeeza to be cost-saving compared to lomitapide. The treatment, which is administered monthly, is now reimbursed and available in the U.S., England and Wales, Canada, Italy, and Germany. Evkeeza's impact on cardiovascular morbidity and mortality is yet to be determined.
January 04, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx's Evkeeza received a positive recommendation from NICE for treatment of HoFH in the U.K., which may lead to increased adoption and sales in the region.
The positive recommendation from NICE for Evkeeza is a significant regulatory milestone that is likely to increase the drug's adoption and usage in the U.K. This could lead to increased revenues from sales in the region, which is a positive indicator for the stock in the short term. The importance is rated high due to the potential revenue impact, but not at the maximum because the overall financial impact depends on the size of the HoFH market in the U.K. and the adoption rate of the treatment. The confidence level is high as regulatory approvals are strong indicators of market expansion and sales growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100